130 related articles for article (PubMed ID: 3089581)
1. Serotherapy of primary rat mammary carcinoma: inhibition by ethylenedinitrilotetraacetic acid but not by [ethylenebis(oxyethylenenitrilo)]tetraacetic acid.
Nakanishi K; Zbar B; Borsos T; Glenn G
Cancer Res; 1986 Aug; 46(8):3886-90. PubMed ID: 3089581
[TBL] [Abstract][Full Text] [Related]
2. Plasma therapy of primary rat mammary carcinoma: dependence of consumption of C3 during absorption of plasma with sepharose derivatives on the anticoagulant.
Nakanishi K; Zbar B; Borsos T
Cancer Res; 1985 Sep; 45(9):4122-7. PubMed ID: 3928150
[TBL] [Abstract][Full Text] [Related]
3. Plasma therapy of primary rat mammary carcinoma: antitumor activity of tumor-bearer plasma adsorbed against inactivated CNBr sepharose or protein A-sepharose.
Sukumar S; Zbar B; Terata N; Langone JJ
J Biol Response Mod; 1984; 3(3):303-15. PubMed ID: 6379113
[TBL] [Abstract][Full Text] [Related]
4. Serotherapy of cancer: cellular changes in primary rat mammary carcinomas after infusion of syngeneic sera absorbed with protein A-Sepharose.
Glenn GM; Szende B; Yano T; Zbar B; Borsos T
Int J Cancer; 1988 Jul; 42(1):76-83. PubMed ID: 3292444
[TBL] [Abstract][Full Text] [Related]
5. Complement activating property of the protein-rich endotoxin (OEP) of Pseudomonas aeruginosa. I. Activation of both the classical and the alternative pathways of guinea pig complement.
Inada K
Jpn J Exp Med; 1980 Feb; 50(1):13-21. PubMed ID: 6770130
[TBL] [Abstract][Full Text] [Related]
6. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction.
Pinckard RN; Olson MS; Giclas PC; Terry R; Boyer JT; O'Rourke RA
J Clin Invest; 1975 Sep; 56(3):740-50. PubMed ID: 808560
[TBL] [Abstract][Full Text] [Related]
7. Studies of the alternate pathway in chelated serum.
Forsgren A; Mclean RH; Michael AF; Quie PG
J Lab Clin Med; 1975 Jun; 85(6):904-12. PubMed ID: 805816
[TBL] [Abstract][Full Text] [Related]
8. Extracts of airborne grain dusts activate alternative and classical complement pathways.
Olenchock SA; Mull JC; Major PC
Ann Allergy; 1980 Jan; 44(1):23-8. PubMed ID: 6766283
[TBL] [Abstract][Full Text] [Related]
9. The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan.
Schenkein HA; Ruddy S
J Immunol; 1981 Jan; 126(1):7-10. PubMed ID: 6778918
[TBL] [Abstract][Full Text] [Related]
10. Alternative complement pathway-dependent ingestion of fluolite particles by human granulocytes.
Arnaout MA; Luscinskas FW; Lionetti FJ; Alper CA; Valeri CR
J Immunol; 1981 Jul; 127(1):278-81. PubMed ID: 6787126
[TBL] [Abstract][Full Text] [Related]
11. Effects of divalent-cation chelators and chloramphenicol on the spatial relationship of the nuclear envelope to chromatin in micronuclei of Chinese hamster cells.
Chai LS; Weinfeld H; Sandberg AA
J Supramol Struct; 1978; 9(4):459-71. PubMed ID: 108479
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic effects of normal sera on lymphoid cells. II. Requirements for inhibition of nonspecific serum cytotoxicity by agarose.
Budzko DB; Kierszenbaum F
Transplantation; 1977 Apr; 23(4):337-42. PubMed ID: 405760
[TBL] [Abstract][Full Text] [Related]
13. Non-covalently bound C3 enhances lysis of rabbit erythrocytes through the alternative pathway.
Hidvégi T; Füst G; Rajnavölgyi E; Kulics J; Gergely J
Immunology; 1985 Dec; 56(4):735-41. PubMed ID: 3935572
[TBL] [Abstract][Full Text] [Related]
14. The septic burned patient: a model for studying the role of complement and immunoglobulins in opsonization of opportunist micro-organisms.
Bjornson AB; Altemeier WA; Bjornson HS
Ann Surg; 1979 Apr; 189(4):515-27. PubMed ID: 109057
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
Kievits F; Kijlstra A
Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
[TBL] [Abstract][Full Text] [Related]
16. Activation of the alternative pathway of complement by Acanthamoeba culbertsoni.
Ferrante A; Rowan-Kelly B
Clin Exp Immunol; 1983 Nov; 54(2):477-85. PubMed ID: 6418422
[TBL] [Abstract][Full Text] [Related]
17. The requirement of specific antibody for the killing of E. coli by the alternate complement pathway in bovine serum.
Hill AW; Shears AL; Hibbitt KG
Immunology; 1978 Jan; 34(1):131-6. PubMed ID: 75177
[TBL] [Abstract][Full Text] [Related]
18. Killing of the S and Re forms of Salmonella minnesota via the classical pathway of complement activation in guinea-pig and human sera.
Clas F; Loos M
Immunology; 1980 Aug; 40(4):547-56. PubMed ID: 6776034
[TBL] [Abstract][Full Text] [Related]
19. Generation of human C3a, C4a, and C5a anaphylatoxins by protein A of Staphylococcus aureus and immobilized protein A reagents used in serotherapy of cancer.
Langone JJ; Das C; Bennett D; Terman DS
J Immunol; 1984 Aug; 133(2):1057-63. PubMed ID: 6610702
[TBL] [Abstract][Full Text] [Related]
20. Complement activation by measles virus cytotoxic antibodies: alternative pathway C activation by hemagglutination-inhibition antibodies but classical activation by hemolysin antibodies.
Ehrnst AC
J Immunol; 1977 Feb; 118(2):533-9. PubMed ID: 402419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
